Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A

In this podcast episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s caregiver on treatment options with factor and nonfactor therapies and how these options can affect strategies for optimizing prophylaxis and improving adherence.
Guy A. Young, MD
Released: October 8, 2021

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:

  • Overcoming challenges to adherence
  • Choice of standard vs extended half-life factor VIII vs emicizumab
  • Safety and efficacy data with emicizumab

Information on this Educational Activity


Guy A. Young, MD

Professor of Pediatrics
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Sanofi, Spark, Takeda, and UniQure.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with the
Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

Paul Coppo, MD, PhD Released: October 21, 2021

Expert commentary on current and emerging treatment options for hemophilia A, from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Released: October 14, 2021

Clinical Care Options (CCO) expert faculty Guy Young, MD, on the evolution of prophylaxis therapy for hemophilia A and adherence challenges with young adult patients

Guy A. Young, MD Released: September 22, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.